Trial reportThe Journal of clinical endocrinology and metabolism2026
Bone turnover in arginine vasopressin deficiency: a comparative study with primary polydipsia and healthy controls.
Trial report in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05890690 (Plasma Copeptin in Response to Oral Urea in Healthy Adults and Patients With Polyuria-polydipsia Syndrome), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Plasma Copeptin in Response to Oral Urea in Healthy Adults and Patients With Polyuria-polydipsia Syndrome: a Double-blind, Randomized, Placebo-controlled Cross-over Proof-of-concept and Pilot Study - The URANOS Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
contextArginine vasopressin (AVP) and oxytocin are neurohormones with opposing effects on bone in preclinical models, while their relevance in humans remains uncertain. Data on bone metabolism in individuals lacking AVP release-and possibly also oxytocin-such as patients with AVP deficiency (AVP-D, also known as central diabetes insipidus) remain scarce, although the limited available evidence suggests a potentially deleterious effect.
objectiveThis study aimed to evaluate bone turnover markers in patients with AVP-D compared to individuals with primary polydipsia (PP) and healthy controls (HC).
methodsThis was a secondary analysis of the prospective URANOS Trial (NCT05890690) conducted from June 2023 to June 2024. After excluding patients on chronic steroid therapy (except budesonide and replacement therapy), prior osteoporotic fractures, long-term antiresorptive treatment, or medications known to adversely affect bone metabolism (eg, aromatase inhibitors), 46 participants were included (HC = 22, AVP-D = 11, PP = 13). All individuals were assessed for bone resorption (C-terminal telopeptide of type I collagen [CTX]) and bone formation (N-terminal propeptide of type I collagen [P1NP]) markers, as well as 25OH-vitamin D, serum calcium, and phosphate. The bone formation index (defined as P1NP/CTX ratio) was calculated.
resultsSerum calcium, phosphate, and P1NP levels were comparable across groups, whereas 25OH-vitamin D concentrations were lower in patients with AVP-D than in HC (P = .031). Median CTX levels were lower in AVP-D (0.373 [0.288-0.513] ng/mL) than in HC (0.592 [0.427-0.729] ng/mL, P = .021), with no difference between PP (0.514 [0.411-0.618] ng/mL) and the other groups. The bone formation index was higher in AVP-D than in HC (P = .036), whereas no difference was observed between PP and either group. In the multivariable linear regression model adjusted for confounders, CTX was lower in AVP-D compared to HC (-0.183; 95% CI, -0.352 to -0.013; P = .036), with no difference compared to PP.
conclusionPatients with AVP-D showed reduced CTX levels and consequently an increased P1NP/CTX ratio compared to HC, whereas no difference was observed between patients with PP and both groups. Overall, these findings do not support major bone metabolic alterations with detrimental effects in AVP-D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.